Research Progress on Clinical Efficacy of Novel Lipid-Lowering Drug PCSK9 Inhibitor
PCSK9 inhibitors,as a novel class of lipid-lowering drug,can significantly reduce low-density lipoprotein cholesterol(LDL-C)levels and further reduce the rate of myocardial infarction on the basis of statin therapy,and reduce the risk of major cardiovas-cular events.This study summarizes the research progress on two PCSK9 inhibitors,Alirocumab and Evolocumab,which have been listed and included in medical insurance in China,and are gradually being widely used in clinical practice.The lipid-lowering efficacy,safety,and efficacy of Alirocumab and Evolocumab are reviewed and compared,aiming to provide better treatment and clinical services for patients with hyperlipemia..The summary of relevant literatures shows that Alirocumab and Evolocumab have good lipid-lowering effects,especially for those who are not suitable for using other lipid-lowering drugs,or those who cannot achieve their lipid-lowering goals with common treatment methods.But in terms of achieving lipid-lowering standards,Alirocumab is superior to Evolocumab.In terms of clinical comprehensive evaluation,Alirocumab is superior to Evolocumab in terms of safety,efficacy,and suitability(although further research is needed to confirm).Alirocumab and Evolocumab,as representative monoclonal antibodies in PCSK9 inhibitors,have definite clinical efficacy and good safety.
万方数据
维普
